Please read the Accreditation Information section of the training page to learn about the requirements for receiving credit or a certificate of completion.
Virtual meeting
Via Zoom
Description
As part of the twice-monthly SUD Care Continuum ECHO® series, Beth Cohen, MD, will provide an overview of the prevalence of anabolic and androgenic steroid use, the associated health risks, and approaches to support patients in discontinuation of use. The didactic will be followed by a de-identified patient case presentation from an ECHO® participant and recommendations from the panel of experts and attendees.
Boston Medical Center's (BMC) drop-in series Substance Use Disorder Care Continuum ECHO® (SUD Care Continuum ECHO®) offers training and support in addiction treatment, with a focus on supporting front line addiction treatment workforce. This includes health providers in Acute Treatment Services (ATS), Crisis Stabilization Services (CSS), Transitional Support Services (TSS), Opioid Treatment Programs (OTP), long-term residential program, sober and recovery homes, primary care, and psychiatry. This free, case-based tele-mentoring program is designed to increase the capacity of health care providers to implement high-quality and evidence-based addiction treatment.
Intended audience
Providers, nurses, social workers, psychologists, peer supports, other clinical staff, and non-clinicians.
Speakers
Beth Cohen, MD
Dr. Beth Cohen is the Medical Director of the GenderCare Center and an Assistant Professor of Medicine at the Boston University Chobanian & Avedisian School of Medicine. Dr. Cohen is a board certified endocrinologist who practices within the Endocrinology, Diabetes, Nutrition and Weight Management Department of Boston Medical Center. She specializes in gender affirming hormone therapy and care for transgender and gender diverse individuals. Additional areas of interest include the evaluation and treatment of hypogonadism (estrogen or testosterone deficiency) and polycystic ovarian syndrome (PCOS).
Objectives
Following this training, participants will have the knowledge to:
- Describe the prevalence of use of anabolic and androgenic steroids among patients with a substance use disorder and the general population.
- Understand the health risks associated with the use of these performance or appearance-enhancing drugs.
- Learn about approaches to supporting patients in discontinuation of use.
Sponsored by
Massachusetts Department of Public Health, Bureau of Substance Addiction Services (DPH/BSAS).
Funding for out of state attendees is provided by the Opioid Response Network (ORN).
Funding for this initiative was made possible (in part) by grant no. 1H79TI085588-02 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
Audience
Providers, nurses, social workers, psychologists, peer supports, other clinical staff, and non-clinicians.
